Federal Register / Vol. 75, No. 32 / Thursday, February 18, 2010 / Notices 7283 

20993, 301–796–6313, e-mail: 

James.Swink@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512625. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On March 18, 2010, the 

committee will discuss, make 

recommendations, and vote on the 

premarket approval application (PMA) 

for the Cardiac Resynchronization 

Therapy Defibrillators (CRT–Ds) 

sponsored by Boston Scientific. The 

sponsor is seeking expanded indications 

for the their CRT–Ds to include patients 

with low left ventricular ejection 

fraction (≤30%) and wide QRS (≥130 

ms) who are NYHA Class II (ischemic or 

non-ischemic etiology) or NYHA Class I 

(ischemic etiology). 

On March 19, 2010, the committee 

will discuss, make recommendations 

and vote on a PMA for the REVO MRI 

Pacemaker System sponsored by 

Medtronic. The REVO MRI Pacing 

System is a pacemaker (with a standard 

pacing indication) that has been 

specifically designed to be safe for the 

MRI environment under certain MR 

scanning conditions. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm, scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before March 11, 2010. 

Oral presentations from the public will 

be scheduled immediately following 

lunch. Those desiring to make formal 

oral presentations should notify the 

contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before March 3, 2010. Time allotted 

for each presentation may be limited. If 

the number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by March 4, 2010. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact AnnMarie 

Williams at 301–796–5966 at least 7 

days in advance of the meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/Advisory

Committees/AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: February 4, 2010. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–3032 Filed 2–17–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Strengthening 

Global Human-Animal Interface 

Activities for Avian Influenza and Other 

Zoonotic Diseases, Funding 

Opportunity Announcement (FOA) 

CK10–001, Initial Review 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting: 

Time and Date: 12 p.m.–2 p.m., April 7, 

2010 (Closed). 

Place: Teleconference. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c)(4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters To Be Discussed: The meeting will 

include the initial review, discussion, and 

evaluation of applications received in 

response to ‘‘Strengthening Global HumanAnimal Interface Activities for Avian 

Influenza and other Zoonotic Diseases, FOA 

CK10–001.’’ 

Contact Person for More Information: 

Gregory Anderson, M.S., M.P.H., Scientific 

Review Officer, CDC, 1600 Clifton Road, NE., 

Mailstop E60, Atlanta, GA 30333, Telephone: 

(404) 498–2293. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: February 11, 2010. 

Andre Tyler, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. 2010–3141 Filed 2–17–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Board of Scientific Counselors, 

Coordinating Center for Infectious 

Diseases, (BSC, CCID) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC), 

announces the following meeting of the 

aforementioned committee: 

Time and Date: 10 a.m.–11 a.m., March 2, 

2010. 

Place: Teleconference. 

Status: Open to the public, the toll free dial 

in number is 1–866–880–0098 with a pass 

code of 9887280. 

Purpose: The BSC, CCID shall advise the 

Secretary, HHS, and the Director, CDC 

concerning strategies and goals for the 

programs and research within the national 

centers; will administer and oversee peer 

review of scientific programs; and monitor 

the overall strategic direction and focus of 

the national centers. 

Matters To Be Discussed: Agenda items 

will include: 

1. Update from Dr. Khabbaz. 

2. Update on H1N1 response. 

3. Update from National Center for HIV/ 

AIDS, Viral Hepatitis, STD, and TB 

Prevention. 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES

7284 Federal Register / Vol. 75, No. 32 / Thursday, February 18, 2010 / Notices 

4. Update from National Center for 

Immunization and Respiratory Diseases. 

5. Update from National Center for 

Emerging and Zoonotic Infectious Diseases. 

6. Plan the May meeting. 

Written comments are welcome and should 

be received by the contact person listed 

below prior to the opening of the meeting. 

Agenda items are subject to change as 

priorities dictate. 

For More Information Contact: Leola 

Mitchell, Office of the Director, CCID, CDC, 

Mailstop E06, 1600 Clifton Road, NE., 

Atlanta, Georgia 30333, Telephone (404) 

639–6405, e-mail: fvp9@cdc.gov. 

The Director, Management Analysis and 

Services Office has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: February 8, 2010. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2010–3056 Filed 2–17–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

National Center for Injury Prevention 

and Control/Initial Review Group, 

(NCIPC/IRG) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC), 

announces the following meeting of the 

aforementioned review group: 

Times and Dates: 8 a.m.–5 p.m., 

March 11, 2010 (Closed). 

8 a.m.–5 p.m., March 12, 2010 

(Closed). 

Place: JW Marriott Hotel Buckhead, 

3300 Lenox Road, Atlanta, Georgia 

30326, Telephone: (404) 262–3344. 

Status: The meetings will be closed to 

the public in accordance with 

provisions set forth in Section 

552b(c)(4) and (6), Title 5, U.S.C., and 

the Determination of the Director, 

Management Analysis and Services 

Office, CDC, pursuant to Section 10(d) 

of Public Law 92–463. 

Purpose: This group is charged with 

providing advice and guidance to the 

Secretary, Department of Health and 

Human Services, and the Director, CDC, 

concerning the scientific and technical 

merit of grant and cooperative 

agreement applications received from 

academic institutions and other public 

and private profit and nonprofit 

organizations, including State and local 

government agencies, to conduct 

research that will expand and advance 

the understanding of violence, its 

causes, and prevention strategies. 

Matters To Be Discussed: The meeting 

will include the review, discussion, and 

evaluation of applications intended to 

expand and advance the understanding 

of violence, its causes, and prevention 

strategies. Requests for Applications are 

related to the following individual 

research announcement: CE10–005, 

Research Grants for Preventing Violence 

and Violence–Related Injury. 

Agenda items are subject to change as 

priorities dictate. 

Contact Person for More Information: 

J. Felix Rogers, PhD, M.P.H., NCIPC, 

CDC, 4770 Buford Highway, NE., 

MailStop F63, Atlanta, Georgia 30341, 

Telephone: (770) 488–4334. 

The Director, Management Analysis 

and Services Office has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities for both CDC and 

the Agency for Toxic Substances and 

Disease Registry. 

Dated: February 10, 2010. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2010–3048 Filed 2–17–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Institutional 

Collaboration Between Liverpool 

School of Tropical Medicine and the 

Centers for Disease Control and 

Prevention on Malaria, Funding 

Opportunity Announcement (FOA) 

CK10–002, Initial Review 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting: 

Time and Date: 12 p.m.—2 p.m., April 12, 

2010 (Closed). 

Place: Teleconference. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c) (4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters To Be Discussed: The meeting will 

include the initial review, discussion, and 

evaluation of applications received in 

response to ‘‘Institutional Collaboration 

between Liverpool School of Tropical 

Medicine and the Centers for Disease Control 

and Prevention on Malaria, FOA CK10–002.’’ 

Contact Person for More Information: 

Gregory Anderson, M.S., M.P.H., Scientific 

Review Officer, CDC, 1600 Clifton Road, NE., 

Mailstop E60, Atlanta, GA 30333, Telephone: 

(404) 498–2293. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: February 10, 2010. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2010–3049 Filed 2–17–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket Number NIOSH 099–C] 

NIOSH Current Intelligence Bulletin— 

Asbestos Fibers and Other Elongate 

Mineral Particles: State of the Science 

and Roadmap for Research, Version 4 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC), 

Department of Health and Human 

Services (HHS). 

ACTION: Notice of Draft Document 

Available for Public Comment. 

SUMMARY: The National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC) 

announces the following revised draft 

document available for public comment 

entitled ‘‘NIOSH Current Intelligence 

Bulletin—Asbestos Fibers and Other 

Elongate Mineral Particles: State of the 

Science and Roadmap for Research, 

Version 4.’’ The document and 

instructions for submitting comments 

can be found at http://www.cdc.gov/ 

niosh/review/public/099–C/. 

Public Comment Period: February 18, 

2010 through April 16, 2010. 

Status: Written comments may be 

mailed to the attention of the NIOSH 

Docket Officer, NIOSH Docket Office, 

Robert A. Taft Laboratories, 4676 

Columbia Parkway (M/S C34), 

Cincinnati, Ohio 45226, telephone (513) 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES